BIO-TECHNE Corp. 10-Q Summary: Quarter Ended September 30, 2025
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for BIO-TECHNE Corporation for the period ended September 30, 2025. The Company develops, manufactures, and sells biotechnology reagents, instruments, and services for research and clinical diagnostic markets. It operates through two primary segments: Protein Sciences and Diagnostics and Spatial Biology.
Key Financial Metrics
| Metric | Q1 2026 (Sep 30, 2025) | Q1 2025 (Sep 30, 2024) |
|---|---|---|
| Net Sales | $286.6 million | $289.5 million |
| Gross Margin | $188.1 million (65.6%) | $183.0 million (63.2%) |
| Operating Income | $47.7 million | $40.0 million |
| Net Earnings | $38.2 million | $33.6 million |
| Diluted EPS | $0.24 | $0.21 |
| Operating Cash Flow | $27.6 million | $63.9 million |
| Cash and Equivalents | $145.0 million | $187.5 million |
| Long-Term Debt | $300.0 million | $346.0 million |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 1% year-over-year. Organic revenue also declined 1%, driven by volume pressure in the Protein Sciences segment, partially offset by favorable performance in Diagnostics and Spatial Biology and a 1% favorable foreign currency impact.
- Profitability: Operating income increased 19% to $47.7 million, and Net Earnings increased 14% to $38.2 million. Gross margin expanded to 65.6% from 63.2% due to product mix changes and reduced restructuring charges.
- Cash Flow: Operating cash flow decreased significantly to $27.6 million from $63.9 million, primarily due to timing differences in payments for operating assets and liabilities.
- Debt: The Company repaid $46.0 million of long-term debt during the quarter, reducing the outstanding balance to $300.0 million.
- Divestiture: The Company completed the sale of its Exosome Diagnostics business, recognizing a $6.8 million recovery of assets held-for-sale and receiving $6.8 million in stock from the buyer (MDxHealth).
Guidance, Outlook, and Risks
- Tax Outlook: The effective tax rate was 20.4%. Management forecasts a consolidated income tax rate for the remainder of fiscal 2026 to range from 26% to 30% (excluding discrete items).
- Capital Expenditures: CapEx for the quarter was $5.4 million. Total CapEx for fiscal 2026 is expected to be approximately $27 million, funded by cash on hand and operating cash flow.
- Wilson Wolf Acquisition: The Company is obligated to acquire the remaining 80.1% of Wilson Wolf Corporation by December 31, 2027, for approximately $1 billion plus potential contingent consideration, triggered by the achievement of EBITDA targets.
- Restructuring: Ongoing restructuring actions to optimize manufacturing processes are expected to incur costs through fiscal 2027. A cumulative impairment charge of $83.1 million was recorded in the prior fiscal year related to the Exosome Diagnostics divestiture.
- Risks: Key risks include integration of acquisitions, supply chain challenges, foreign currency fluctuations, and the outcome of legal proceedings, though no material legal proceedings were reported as of November 5, 2025.
Investor Verification Checklist
- Verify the sustainability of the 65.6% gross margin given the exclusion of held-for-sale business impacts.
- Monitor the timing and funding of the mandatory $1 billion Wilson Wolf acquisition payment due by late 2027.
- Assess the impact of the $6.8 million non-cash recovery from the Exosome Diagnostics sale on future earnings quality.
- Review the significant decline in operating cash flow ($27.6M vs $63.9M) to determine if it is a temporary timing issue or a structural change in working capital.
- Confirm the status of the $405 million remaining under the Company's stock repurchase plan.